The Class 1 new drug, NMM tumor therapeutic DNA vaccine naked plasmid injection (acceptance number: CXSL2250571), developed by Gu'an Dingtai Haigui Biotechnology Co., Ltd., has obtained clinical trial approval from the National Medical Products Administration. The proposed indications are advanced solid tumors and recurrent/refractory lymphoma.

NMM tumor therapeutic DNA vaccine is a type of DNA vaccine drug that is administered by local injection with the aim of inducing systemic anti-tumor immune response.

The Drug Safety Evaluation Research Center of Shandong Xinbo Pharmaceutical Research Co., Ltd. undertook the methodological establishment and validation, tissue distribution research, and non clinical safety evaluation research of this variety. The relevant research data provided support for the clinical trial permit of this variety.